Revvity 

€69.76
122
-€3.04-4.18% 今天

統計

當日最高
72.6
當日最低
69.46
52週高點
100.2
52週低點
69.64
成交量
-
平均成交量
-
市值
0
本益比
-
股息殖利率
0.33%
股息
0.23

即將到來

股息

0.33%股息殖利率
May 26
€0.06
Feb 26
€0.06
Nov 25
€0.06
Aug 25
€0.06
May 25
€0.06
10年成長
不適用
5年成長
不適用
3年成長
不適用
1年成長
不適用

財報

5May預期
Q4 2025
下一步
0.87
1.06
1.25
1.44
預期EPS
0.86856946132
實際EPS
不適用

其他人也在關注

此清單是根據在 Stock Events 上追蹤 PKN.STU 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Show more...
執行長
Dr. Prahlad R. Singh Ph.D.
員工
16000
國家
美國
ISIN
US7140461093

上市

0 Comments

分享你的想法

FAQ

Revvity 今天的股價是多少?
PKN.STU 目前價格為 €69.76 EUR,過去 24 小時下跌了 -4.18%。在圖表上更密切關注 Revvity 股票的表現。
Revvity 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Revvity 的股票以代號 PKN.STU 進行交易。
Revvity 的股價在上漲嗎?
PKN.STU 股票較上週下跌 -12.95%,本月下跌 -4.02%,過去一年 Revvity 下跌 -16.61%。
Revvity 下一次財報日期是什麼時候?
Revvity 將於 May 05, 2026 公布下一次財報。
Revvity 上一季度的財報如何?
PKN.STU 上一季度的財報為每股 1.44 EUR,預估為 1.33 EUR,帶來 +8.29% 的驚喜。下一季度的預估財報為每股 不適用 EUR。
Revvity 會發放股息嗎?
是的,PKN.STU 的股息每 每季 發放一次。每股最新股息為 0.06 EUR。截至今日,股息殖利率(FWD)% 為 0.33%。
Revvity 有多少名員工?
截至 April 29, 2026,公司共有 16,000 名員工。
Revvity 位於哪個產業?
Revvity從事於Health & Wellness產業。
Revvity 何時完成拆股?
Revvity 最近沒有進行任何拆股。
Revvity 的總部在哪裡?
Revvity 的總部位於 美國 的 Waltham。